Wenfeng Fang

14PUBLICATIONS
82CO-AUTHORS
Molecular targetsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)ChemotherapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 24, 2026
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

|Mar 24, 2026
The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Mar 04, 2026
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Huaqiang Zhou, Hongyun Zhao, Xue Hou

|Dec 13, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.

Wenfeng Fang, Jian Fang, Panwen Tian

|Aug 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.

Shaodong Hong, Qiming Wang, Ying Cheng

|Apr 22, 2025
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao

Pageof 3

Frequent Collaborators

9 joint publications

Li Zhang

5 joint publications

Hongyun Zhao

4 joint publications

Yan Huang

3 joint publications

Yuxiang Ma